Adoptive Immunotherapy With CMV-specific Cytotoxic T Lymphocytes for Stem Cell Transplant Patients With Refractory CMV Infections
- 1 April 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Immunotherapy
- Vol. 35 (3), 293-298
- https://doi.org/10.1097/cji.0b013e31824300a2
Abstract
Adoptive immunotherapy with cytomegalovirus (CMV)-specific cytotoxic T lymphocytes (CTL) is an effective strategy for preventing and treating viral reactivation after allogeneic stem cell transplantation (SCT). We have shown previously that CMV CTL can be generated in 1 to 2 weeks by stimulating donor lymphocytes with peptide mixes derived from full-length pp65 and IE1. We conducted a multi-institutional study of CMV-specific CTL for patients with persistent or anti–viral-resistant CMV infections after allogeneic SCT, to determine the safety, feasibility, and immunologic effects of this approach. We were successful in stimulating CTL from 10/10 donors with pooled CMV overlapping peptide mixes. Five of the 7 subjects who met infusion criteria had new onset CMV-specific CTL activity detected within 4 to 6 weeks after infusion. Of the 2 subjects who did not have immunologic responses after infusion, 1 received CTL with a low viability after thawing, and the other patient received cyclosporine A and systemic corticosteroids at the time of the infusion, achieving only a low, transient increase (10%) in pp65-specific activity. There was no graft-versus-host disease attributable to these infusions. These findings indicate that the infusion of CTL stimulated over 1 to 2 weeks with overlapping CMV peptides can result in virus-specific immune reconstitution in SCT recipients, without exacerbations of graft-versus-host disease.Keywords
This publication has 21 references indexed in Scilit:
- Cytolytic CD4 cells: Direct mediators in infectious disease and malignancyCellular Immunology, 2010
- Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapyHuman Immunology, 2004
- Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell linesThe Lancet, 2003
- Inhibition of ex vivo-expanded cytotoxic T-lymphocyte function by high-dose cyclosporineTransplantation, 2003
- B Lymphoblastoid Cell Lines as Efficient APC to Elicit CD8+ T Cell Responses Against a Cytomegalovirus AntigenThe Journal of Immunology, 2000
- Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency.JCI Insight, 1997
- Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind studyBlood, 1996
- Principles for Adoptive T Cell Therapy of Human Viral DiseasesAnnual Review of Immunology, 1995
- Ganciclovir Prophylaxis To Prevent Cytomegalovirus Disease after Allogeneic Marrow TransplantAnnals of Internal Medicine, 1993
- Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell ClonesScience, 1992